MedTrace Logo

Plasma Concentration of Lidocaine and Bupivacaine Axillary BPB Mixture Solutions [PCLBAxMix]

NCT03527836 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-07-22

No results posted yet for this study

Summary

The doses of local anesthetics can be decreased with the use of ultrasound guidance. In case of using mixture solutions the benefits and drawbacks are controversial. The plasma concentrations were not studied up to this time in this kind of settings, so investigators believe that this is the first work that shows how lidocaine change the plasma concentration of bupivacaine after axillary approach to brachial plexus employed with different dilute and mixed solutions for upper limb surgery in trauma patients.

Conditions

  • Arm Injury

Interventions

DRUG

Lidocaine brachial plexus block

Combined Axillary-supraclavicular approach to brachial plexus with lidocaine

DRUG

Bupivacaine brachial plexus block

Combined Axillary-supraclavicular approach to brachial plexus with bupivacaine

DRUG

Mixture brachial plexus block

Combined Axillary-supraclavicular approach to brachial plexus with mixture solution of 20 ml bupivacaine 0.5% and 10 ml lidocaine 1%

Sponsors & Collaborators

  • University of Pecs

    lead OTHER

Principal Investigators

  • Robert G Almasi, PhD. habil · University of Pecs, Medical School, Pain Medicine Dept.of Anesth Int Care

  • Barbara Rezman, MD · University of Pecs, Medical School, Dept.of Anesth Int Care

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-03-17
Primary Completion
2021-12-17
Completion
2022-01-17

Countries

  • Hungary

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03527836 on ClinicalTrials.gov